

# Market of Paclitaxel Injection in China

<https://marketpublishers.com/r/M2309CCA9A3EN.html>

Date: July 2010

Pages: 51

Price: US\$ 9,683.00 (Single User License)

ID: M2309CCA9A3EN

## Abstracts

Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.

Chinese paclitaxel injection industry has witnessed significant development from 2005~2009. On the one hands, since 2005, China's government has issued a series of policies related to China's pharmaceutical industry like healthcare reform. What they effect the paclitaxel injection industry? On the other hand, paclitaxel injection has become the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?

For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the forbidden for the develop of natural yew and the development for planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price and get less profit. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How the paclitaxel APIs and paclitaxel injection manufactures replied for this change? In 2009, Sichuan Jiufeng Pharmaceutical

Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.

Chinese paclitaxel injection industry has witnessed significant development from 2005~2009. On the one hands, since 2005, China's government has issued a series of policies related to China's pharmaceutical industry like healthcare reform. How do they influence the paclitaxel injection industry? On the other hand, paclitaxel injection has enjoyed the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?

For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the increasing cultivated planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How did the paclitaxel APIs and paclitaxel injection manufacturers respond to this change? In 2009, Sichuan Jiufeng Pharmaceutical Co., Ltd. (Sichuan Jiufeng), the largest producer of paclitaxel injection in China, has increased its output of paclitaxel injection greatly because of the great demand, and then what is the performance of Sichuan Jiufeng in 2010?

What's more, paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms. How do the pharmaceutical distribution companies distribute the paclitaxel injection, and how does the medicine bidding and purchase platforms for paclitaxel injection are operated?

Besides the aspects mentioned above, what is the production distribution of paclitaxel APIs? What is the development trend of China's paclitaxel injection? CCM has carried out in-depth research and analysis on each active producer, as well as the whole industry to figure out these questions.

In this report, you can obtain info about:

Production distribution of paclitaxel APIs

General situation of paclitaxel injection production and its manufacturers

Top 2 pharmaceutical distribution companies in China

Medicine bidding and purchasing platforms

Import and export paclitaxel injection analysis, as well as paclitaxel APIs export analysis

Consumption situation of paclitaxel injection

Government policy for paclitaxel injection and quality standards of paclitaxel injection

circulation model of paclitaxel injection in China

With the information covered in the report, readers can see the general production and consumption situation, circulation model, as well as APIs supply situation for China paclitaxel injection manufacturers in China, which are beneficial for the investors' decision making.

## Contents

Executive summary

### **I DEVELOPMENT OF POLICY ENVIRONMENT FOR PACLITAXEL INJECTION IN CHINA**

- I-1 Regulation in GMP about paclitaxel injection
- I-2 Regulation about paclitaxel injection in CP 2000

### **II PRODUCTION OF PACLITAXEL INJECTION IN CHINA**

- II-1 Production data from 2005 to 2009
- II-2 Regional distribution of paclitaxel injection production
- II-3 Summary of paclitaxel injection manufacturers in China, 2008&2009
- II-4 Competition analysis of paclitaxel injection producers

### **III PRODUCTION OF PACLITAXEL APIS IN CHINA**

### **IV CHINA'S PACLITAXEL INJECTION DISTRIBUTION MODEL**

- IV-1 Pharmaceutical distribution business in China
  - IV-1.1 Development history of pharmaceutical distribution business in China
  - IV-1.2 China's major regional market share of pharmaceutical distribution business
  - IV-1.3 Sales value and concentration of pharmaceutical distribution business in China
- IV-2 Introduce distribution of paclitaxel injection with Chinese characteristic

### **V CHINA'S MEDICINE BIDDING AND PURCHASING PLATFORM**

- V-1 Background of medicine bidding and purchasing platform
- V-2 Flow chart of medicine bidding and purchasing platform
- V-3 Top two pharmaceutical distribution companies

### **VI CONSUMPTION OF PACLITAXEL INJECTION IN CHINA**

- VI-1 Overview of anticancer drugs in China
  - VI-1.1 Consumption situation of natural anticancer drugs
- VI-2 Consumption situation of paclitaxel injection
  - VI-2.1 Consumption in end-user sectors

VI-2.1.1 NSCLC

VI-2.1.2 Breast cancer

VI-2.1.3 Ovarian cancer

VI-2.2 Distribution of paclitaxel injection consumption in top five provinces

VI-3 Consumption potential analysis of paclitaxel injection in next 5 years

VI-3.1 Influencing factors for consumption

VI-3.2 Forecast consumption of paclitaxel injection in China, 2010-2015

## **VII IMPORT AND EXPORT SITUATION IN 2009**

VII-1 Import and export situation for paclitaxel injection

VII-2 Export situation for paclitaxel APIs

## **VIII RESOURCE OF YEW IN CHINA**

## **IX PROFILE OF MAJOR MANUFACTURERS OF PACLITAXEL INJECTION IN CHINA**

### **LISTS OF TABELS**

Table I-1 Regulations involving paclitaxel and its related products

Table I-2 Paclitaxel export tax rebate, 2005 to now

Table I-1.1 Standard of purified water in China's GMP

Table I-1.2 Quality standard of purified water

Table I-1.3 Standard of air cleanliness in China's GMP

Table I-2.1 CP 2000 of paclitaxel injection of China

Table II-3.1 Active paclitaxel injection manufacturers in China, 2010

Table II-3.1 Active paclitaxel injection manufacturers situation in China, 2010

Table II-3.2 Product situation of active paclitaxel injection manufacturers in China, 2010

Table IV-1.3.1 Sales value of pharmaceutical distribution companies in China, 2003-2009

Table VI-1.1 Market share of anticancer drugs in China, 2005-2009

Table VI-1.1.1 Sales value and market share of natural anticancer preparations in China, 2009

Table VI-2.1 Consumption volume of paclitaxel injection in China, 2005-2009

Table VI-2.2 Sales value and growth rate of paclitaxel injection in China, 2005-2009

Table VI-2.1.1.1 Number and growth rate of NSCLC patients in China, 2005-2009

Table VI-2.1.1.2 Consumption volume and growth rate of paclitaxel injection for NSCLC in China, 2005-2009

Table VI-2.1.2.1 Number and growth rate of breast cancer patients in China, 2005-2009

Table VI-2.1.2.2 Consumption volume and growth rate of paclitaxel injection for breast cancer in China, 2005-2009

Table VI-2.1.3.1 Number and growth rate of ovarian cancer patients in China, 2005-2009

Table VI-2.1.3.2 Consumption volume and growth rate of paclitaxel injection for ovarian cancer in China, 2005-2009

Table VI-2.2.1 Sales value and market share of paclitaxel injection in top five provinces in China, 2009

Table VII-1.1 Paclitaxel injection import situation in China, 2009

Table VII-1.2 Paclitaxel injection export situation in China, 2009

Table VII-2.1 Monthly export value of paclitaxel APIs in China, 2009

Table VII-2.2 Major export destinations of paclitaxel APIs from China, 2009

Table VII-2.3 Major exporters of paclitaxel APIs in China, 2009

Table VIII-1 Yew planting distribution in China, 2007-2009, strains

Table VIII-2 Cultivated yew planting distribution in China, 2007-2009, strains

## **LIST OF FIGURERS**

Figure II-1.1 Production value of paclitaxel injection in China, 2005-2009

Figure II-2.1 Production value distribution of paclitaxel injection in China, 2009, USD

Figure II-2.2 Number of paclitaxel injection manufacturers in different provinces, 2009

Figure II-2.3 Production value structure of paclitaxel injection in China, 2009

Figure III-1.1 Production value of paclitaxel APIs in China, 2005-2009

Figure III-2.1 Production value distribution of paclitaxel APIs in China, 2009, USD

Figure III-2.2 Number of paclitaxel injection manufacturers in different provinces, 2009

Figure III-2.3 Production value structure of paclitaxel APIs in China, 2009

Figure IV-1 Situation of pharmaceutical distribution

Figure IV-1.1.1 Development of pharmaceutical distribution business in China

Figure IV-1.2.1 Geographical distribution of pharmaceutical distribution business by sales value in China, 2009

Figure IV-1.2.2 Market share of pharmaceutical distribution business in China by sales value, 2009

Figure IV-1.3.1 Sales value and market share of top 3 pharmaceutical distribution companies in China, 2003-2009

Figure IV-2.1 Circulation of paclitaxel injection with Chinese characteristic

Figure V-2.1 Flow chart of bidding and purchasing platform

Figure V-3.1 Main business lines of Sinopharm

Figure V-3.1 Main business lines of Shanghai Pharmaceutical

Figure VI-1.1 Sales value and growth rate of anticancer drugs in China, 2005-2009

Figure VI-2.1 Consumption pattern of paclitaxel injection by sales value in China, 2009

Figure VI-2.2 Consumption volume of paclitaxel injection in major segments in China, 2009

Figure VI-3.1.1 CAGR of consumption volume of paclitaxel injection in major end use segments, 2005-2009

Figure VI-3.2.1 Forecast on consumption volume of paclitaxel injection in China, 2010-2014

Figure VI-3.2.2 Forecast on consumption of paclitaxel injection in NSCLC in China, 2010-2014

Figure VI-3.2.3 Forecast on consumption of paclitaxel injection in breast cancer in China, 2010-2014

Figure VI-3.2.4 Forecast on consumption of paclitaxel injection in ovarian cancer in China, 2010-2014

Figure VIII-1 Number of cultivated yews in China, 2007-2009

Figure VIII-2 Geographical distribution of yew's planting amount in China, 2009

## **COMPANIES MENTIONED**

Sichuan Jiufeng Pharmaceutical Co., Ltd., Chongqing Taiji Industry (Group)Co., Ltd., Hainan Haiyao Joint-stock Co., Ltd., Hainan Quanxing Yaoye Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd.

## I would like to order

Product name: Market of Paclitaxel Injection in China

Product link: <https://marketpublishers.com/r/M2309CCA9A3EN.html>

Price: US\$ 9,683.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M2309CCA9A3EN.html>